Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nikolas von Bubnoff

Showing results (1-10 of 165) with videos related to

Pageof 17
Sort By:
Therapeutic Advances in Hematology|April 5, 2013
Prognostic Significance of Treatment Response in CML in View of Current Recommendations for Treatment and MonitoringNikolas von Bubnoff
Blood|March 27, 2025
Taming JAK cytokine release in haplo-transplantNikolas von Bubnoff
Oncology Research and Treatment|July 11, 2017
Liquid Biopsy: Approaches to Dynamic Genotyping in CancerNikolas von Bubnoff
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 3, 2018
Ponatinib: A Third-Generation Inhibitor for the Treatment of CMLJulius Wehrle, Nikolas von Bubnoff
Deutsches Arzteblatt International|March 12, 2010
Chronic myelogenous leukemia: treatment and monitoringNikolas von Bubnoff, Justus Duyster
Cancers|April 13, 2024
Real-World Electronic Medical Records Data Identify Risk Factors for Myelofibrosis and Can Be Used to Validate Established Prognostic ScoresMax Kappenstein, Nikolas von Bubnoff
Anticancer Research|July 3, 2019
Extracellular Vesicles: Subcellular Organelles With the Potential to Spread Cancer ResistanceFanny Ender, Nikolas VON Bubnoff, Frank Gieseler
The New England Journal of Medicine|July 30, 2020
Ruxolitinib for Acute Graft-versus-Host Disease. ReplyRobert Zeiser, Nikolas von Bubnoff, Gérard Socié
Cell Communication and Signaling : CCS|June 14, 2013
Asymmetric kinase dimer formation is crucial for the activation of oncogenic EGFRvIII but not for ERBB3 phosphorylationRama Krishna Kancha, Nikolas von Bubnoff, Justus Duyster
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|April 24, 2014
Ponatinib: a third-generation inhibitor for the treatment of CMLJulius Wehrle, Heike L Pahl, Nikolas von Bubnoff
Pageof 17

Showing results (1-10 of 165) with videos related to

Sort By:
Pageof 17
Therapeutic Advances in Hematology|April 5, 2013
Prognostic Significance of Treatment Response in CML in View of Current Recommendations for Treatment and MonitoringNikolas von Bubnoff
Blood|March 27, 2025
Taming JAK cytokine release in haplo-transplantNikolas von Bubnoff
Oncology Research and Treatment|July 11, 2017
Liquid Biopsy: Approaches to Dynamic Genotyping in CancerNikolas von Bubnoff
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 3, 2018
Ponatinib: A Third-Generation Inhibitor for the Treatment of CMLJulius Wehrle, Nikolas von Bubnoff
Deutsches Arzteblatt International|March 12, 2010
Chronic myelogenous leukemia: treatment and monitoringNikolas von Bubnoff, Justus Duyster
Cancers|April 13, 2024
Real-World Electronic Medical Records Data Identify Risk Factors for Myelofibrosis and Can Be Used to Validate Established Prognostic ScoresMax Kappenstein, Nikolas von Bubnoff
Anticancer Research|July 3, 2019
Extracellular Vesicles: Subcellular Organelles With the Potential to Spread Cancer ResistanceFanny Ender, Nikolas VON Bubnoff, Frank Gieseler
The New England Journal of Medicine|July 30, 2020
Ruxolitinib for Acute Graft-versus-Host Disease. ReplyRobert Zeiser, Nikolas von Bubnoff, Gérard Socié
Cell Communication and Signaling : CCS|June 14, 2013
Asymmetric kinase dimer formation is crucial for the activation of oncogenic EGFRvIII but not for ERBB3 phosphorylationRama Krishna Kancha, Nikolas von Bubnoff, Justus Duyster
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|April 24, 2014
Ponatinib: a third-generation inhibitor for the treatment of CMLJulius Wehrle, Heike L Pahl, Nikolas von Bubnoff
Pageof 17